Related Experiment Videos
The double-edged sword of daptomycin: a case of daptomycin-induced eosinophilic pneumonia
Mohammed Najdat Seijari1, Fayaz Khan1, Taraneh Zamani1
1Department of Internal Medicine, Good Samaritan Hospital, TriHealth, 375 Dixmyth Ave, Mount Auburn neighborhood, Cincinnati, OH 45220, United States.
Abstract:
Daptomycin is an effective antibiotic for resistant gram-positive infections, including MRSA and VRE, but can rarely cause daptomycin-induced eosinophilic pneumonia (DIEP). We present a 73-year-old woman treated for prosthetic joint infection who developed acute hypoxemic respiratory failure and peripheral eosinophilia after 21 days of daptomycin therapy. Chest imaging showed bilateral upper lobe consolidations. Symptoms resolved rapidly after stopping daptomycin, without corticosteroid use. This case highlights the need for early recognition of DIEP in patients presenting with new respiratory symptoms and eosinophilia during daptomycin therapy, enabling timely discontinuation and reducing potential morbidity.
Insights
Daptomycin can rarely cause daptomycin-induced eosinophilic pneumonia (DIEP), a serious lung condition. Early recognition and stopping daptomycin quickly can resolve symptoms without further treatment.
Area of Science:
- Infectious Diseases
- Pulmonology
- Pharmacology
Background:
- Daptomycin is a crucial antibiotic for treating resistant Gram-positive infections like MRSA and VRE.
- Daptomycin-induced eosinophilic pneumonia (DIEP) is a rare but serious adverse effect.
- Prompt diagnosis and management of DIEP are essential to prevent morbidity.
Related Concept Videos
Atypical Pneumonia
Diphtheria
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...